Oral Iloprost
Chemoprevention of Lung Cancer and Its Recurrence
Phase 2Active
Key Facts
About PHAIT
PHAIT is pioneering a novel approach to oncology by focusing on prevention rather than treatment, targeting the world's leading cancer killer, lung cancer. Its lead asset is oral Iloprost, a well-tolerated drug with decades of clinical use in other indications, which demonstrated efficacy in reducing pre-cancerous bronchial dysplasia in a Phase II study. The company holds exclusive worldwide licenses and method-of-treatment patents, positioning it to address a vast, underserved market of at-risk individuals. As a private, pre-revenue entity, PHAIT is planning further clinical studies to advance its chemoprevention strategy.
View full company profile